drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Humanized monoclonal antibody targeting HER2/ERBB2; binds the extracellular domain to inhibit downstream PI3K/AKT and MAPK signaling, promote receptor internalization, and mediate ADCC.
nci_thesaurus_concept_id
C1647
nci_thesaurus_preferred_term
Trastuzumab
nci_thesaurus_definition
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)
drug_mesh_term
Trastuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized monoclonal antibody against HER2/ERBB2 that binds the extracellular domain to block receptor signaling (PI3K/AKT, MAPK), promote receptor internalization and reduced dimerization, and mediate antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing tumor cells.
drug_name
Trastuzumab
nct_id_drug_ref
NCT07062263